• Welcome to the Bio Law Blog. Our blog shares insights into intellectual property law for biologic medicines and related regulatory and legislative developments. We started this blog to engage in a conversation about the rapidly developing U.S. biosimilars pathway (the Biologics Price Competition and Innovation Act) and the recent surge in approvals for cutting-edge biologic products, such as siRNAs and cell-based and gene therapies. These new biologic products are changing medicine and posing new intellectual property questions and challenges. We also analyze developments in written description and enablement law for antibodies, the impact of Section 101 on biotech discoveries, and the increasing role of the Patent Trial and Appeal Board in reviewing biotech patents. We share a perspective as trial lawyers immersed in biology and biotech patent law.

    We are excited to be part of these transformative times for biologic medicines and to discuss them with you. We hope you enjoy our blog, and we welcome any questions, comments or suggestions.

    Subscribe for updates here.

    Show Filters

    Recent Posts

    • Bio Law Blog
      May 01, 2024
      Potential Effects of the Inflation Reduction Act on Orphan Drug Development
    • Bio Law Blog
      July 30, 2021
      Interchangeable Biosimilars Have Arrived in the U.S.
    • Bio Law Blog
      June 17, 2021
      BPCIA Survives Challenge to the Affordable Care Act at Supreme Court
    • Bio Law Blog
      Feb. 18, 2021
      DC District Court Provides Guidance as to the Meaning of ‘Protein’ Under the BPCIA
    • Bio Law Blog
      Nov. 30, 2020
      Third-Generation Vaccines Take Center Stage in Battle Against COVID-19
    • Bio Law Blog
      July 01, 2020
      In Two Life Sciences Cases, the Supreme Court Declines to Address the Constitutionality of IPRs of Pre-AIA Patents

    Featured Perspectives

    • Announcements
      July 28, 2021
      Lisa Kobialka Named to Managing IP's 2021 Top 250 Women in IP List
    • Announcements
      June 01, 2021
      Hannah Lee, Josh Winefsky Named Law360 Rising Stars
  • Perspectives